Business
NeuroOne Reports Fiscal Q1 2026 Financial Results; Expects Product Revenue of At Least $10.5 Million in Fiscal Year 2026
Nearly 50% of all Ablations Since OneRF(R) Ablation System Product Launch in 2024 were Performed in Fiscal Q1 2026, Showing Growing Adoption Following FDA 510(k) Clearance, Successfully Completed Nine Trigeminal Neuralgia Cases to Date, with All Pati...
About this update from Neuroone Medical Technologies Corporation
[{"type":"image","caption":"","headline":"NeuroOne Reports Fiscal Q1 2026 Financial Results; Expects Product Revenue of At Least $10.5 Million in Fiscal Year 2026","size":{"original":{"width":140,"height":70,"url":"https://media.zenfs.com/en/newsmediawire_165/6e29368af07e7c003454bc6560423ba4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/61CM7UIIJoR34ZjwWwyL7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6e29368af07e7c003454bc6560423ba4","width":140,"height":70}}},{"type":"text","content":"Nearly 50% of all Ablations Since OneRF(R) Ablation System Product Launch in 2024 were Performed in Fiscal Q1 2026, Showing Growing Adoption","length":140,"tagName":"p"},{"type":"text","content":"Following FDA 510(k) Clearance, Successfully Completed Nine Trigeminal Neuralgia Cases to Date, with All Patients Reportedly Pain Free*","length":135,"tagName":"p"},{"type":"text","content":"Management to Host Conference Call Today at 8:30 a.m. Eastern Time","length":66,"tagName":"p"},{"type":"text","content":"EDEN PRAIRIE, MINN. - February 17, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results and a business update for the first quarter of fiscal year 2026 ended December 31, 2025.","length":403,"tagName":"p"},{"type":"text","content":"Company Highlights","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The Company expects an increase in product revenue to at least $10.5 million in fiscal year 2026, representing an increase of at least 17% when compared to product revenue of $9.1 million in fiscal year 2025.","length":208,"tagName":"p"}]},{"val":[{"type":"text","content":"Successfully received FDA 510(k) Clearance for OneRF(R) Trigeminal Nerve Ablation System to treat facial pain ahead of schedule, further validating the OneRF(R) technology platform and offering alternatives to pharmaceutical and invasive surgical treatments. To date, the Company successfully completed nine cases using radiofrequency lesions for the treatment of facial pain, a completely new market for NeuroOne.","length":414,"tagName":"p"}]},{"val":[{"type":"text","content":"Advanced discussio...